These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20107162)

  • 1. StatBite: New drug approvals in Japan: a comparison of review times and number of employees.
    J Natl Cancer Inst; 2010 Feb; 102(3):150. PubMed ID: 20107162
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical development and review times for new drugs in Japan: associated factors.
    Ishibashi T; Yasuda K; Kusama M; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Oct; 88(4):487-91. PubMed ID: 20739921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K; Tsutani K
    Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Review process of new oncology drug application in Japan--role of MD reviewer].
    Fujiwara Y
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):196-203. PubMed ID: 9987519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug approval process in Japan.
    Hayakawa T
    Curr Opin Biotechnol; 1999 Jun; 10(3):307-11. PubMed ID: 10361082
    [No Abstract]   [Full Text] [Related]  

  • 10. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 12. Statisticians in European regulatory agencies.
    Skovlund E
    Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market.
    Hashitera Y; Saotome C; Yamamoto H
    Drug Discov Today; 2013 Nov; 18(21-22):1109-16. PubMed ID: 23856327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text]